Celsion's Phase III trial of ThermoDox to continue
This article was originally published in Clinica
Executive Summary
Celsion's trial of its ThermoDox heat-activated therapy for cancer will continue on track, having passed a Data Monitoring Committee (DMC) assessment which will enable the company to keep enrolling patients. However, the global Phase III HEAT study, a pivotal trial of ThermoDox in combination with radiofrequency ablation (RFA) for primary liver cancer, may not yet resume enrollment of patients in Japan.
You may also be interested in...
ITF Has A Fight On Its Hands In Duchenne
The group’s new muscular dystrophy pill seems unlikely to cut into Sarepta’s sales.
AbbVie Needs To Freshen Up
With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.
AstraZeneca Pays $2bn To Keep Up With The Joneses
Bristol Myers Squibb and Lilly have recently done billion-dollar radiopharmaceuticals deals, and now the UK group wants a piece of the market. But can it make its Fusion fusion work?